Table 2 Univariable analyses of overall survival after BM among patients with EGFR-mutated NSCLC (n = 113)
Factors | n (%) | P | 95% CI |
|---|---|---|---|
Sex | |||
 Male | 44 (38.9%) | 0.38 | 0.47–1.34 |
 Female | 69 (61.1%) |  |  |
Age | |||
  ≤ 65 years | 91 (80.5%) | 0.52 | 0.67–2.24 |
  > 65 years | 22 (19.5%) |  |  |
Histological type | |||
 Adenocarcinoma | 113 (100%) | – | – |
Epidermal growth factor receptor gene mutation | |||
 Exon 19 | 52 (46.0%) | 0.13 | 0.94–1.61 |
 Exon 21 | 61 (54.0%) |  |  |
Number of brain metastases | |||
  ≤ 3 | 57 (50.3%) | < 0.01 | 1.72–5.30 |
  > 3 | 56 (49.6%) |  |  |
Maximum size of brain metastases | |||
  ≤ 2 cm | 81 (71.7%) | 0.33 | 0.75–2.36 |
  > 2 cm | 32 (28.3%) |  |  |
Symptoms associated with brain metastasis | |||
 No | 67 (59.3%) | 0.62 | 0.51–1.50 |
 Yes | 46 (40.7) |  |  |
ECOG score | |||
  ≤ 2 | 83 (73.5%) | < 0.01 | 2.84–8.11 |
  > 2 | 30 (26.5%) |  |  |
Treatment | |||
 None | 18 (15.9%) | < 0.01 | 0.55–0.86 |
 Radiotherapy | 27 (23.9%) |  |  |
 Targeted therapy in previously TKI-naïve patients | 14 (12.4%) |  |  |
 Chemotherapy | 15 (13.3%) |  |  |
 Targeted combined radiotherapy | 39 (34.5%) |  |  |